Abstract
Assessment of the human epidermal growth factor receptor-2 (Her2/ErbB2) and estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer has been an accepted standard to predict clinical outcome. Expression of these receptors in primary breast cancer has also been an important predictor of visceral organ metastasis. Many studies of breast cancer have reported risk factors for brain metastasis that include Her2/ErbB2 positivity, ER negativity, and negativity for all the above three receptors. However, it is not clear whether expression of these receptors would persist subsequent to brain metastasis. To address this possibility, we analyzed different breast cancer brain metastases (BCBM) for the expression of Her2/ErbB2, ER, and PR by immunohistochemistry procedure. The results showed that BCBM are heterogeneous in the receptor expression: Five BCBMs were Her2/ErbB2-positive and one negative; four BCBMs were ER-positive, and two were negative; five BCBMs were PR-positive and one negative. However, expression of these receptors in their combination is also heterogeneous: Four BCBMs were positive for all of the Her2/ErbB2, ER, and PR; one BCBM was positive for Her2/ErbB2 and PR but negative for ER; one BCBM was positive for PR but negative for Her2/ErbB2/ER. Similar heterogeneity in the expression of these receptors was also observed in primary tumors. Importantly, BCBM tumors that were assigned as ER- and PR-positive contained tumor cells that lacked expression of these receptors in other regions of the biopsies. Taken together, our findings indicate that the BCBM exhibit heterogeneity in the expression amounts of Her2/ErbB2, ER, and PR, which could be a result of the influence of tumor microenvironment in the brain or different tumor cells populating the metastatic region.
Similar content being viewed by others
References
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69(12):4951–3. doi:10.1158/0008-5472.CAN-09-0099.
Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw : JNCCN. 2009;7(10):1060–96.
Rao US, Hoerster NS, Thirumala S, Rao PS. The influence of metastatic site on the expression of CEA and cellular localization of beta-catenin in colorectal cancer. J Gastroenterol Hepatol. 2013;28(3):505–12. doi:10.1111/jgh.12083.
Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004;64(9):3037–45.
Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res : BCR. 2005;7(4):143–8. doi:10.1186/bcr1041.
Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, et al. Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proc Natl Acad Sci U S A. 2013;110(12):4598–603. doi:10.1073/pnas.1218682110.
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.
Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 2014;124(2):859–70. doi:10.1172/JCI70941.
Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791–9. doi:10.1038/nrc2212.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28(16):2784–95. doi:10.1200/JCO.2009.25.6529.
Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res : BCR. 2004;6(6):240–5. doi:10.1186/bcr938.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.
Olivotto IA, Truong PT, Speers CH, Bernstein V, Allan SJ, Kelly SJ, et al. Time to stop progesterone receptor testing in breast cancer management. J Clin Oncol : Off J Am Soc Clin Oncol. 2004;22(9):1769–70. doi:10.1200/JCO.2004.99.251.
Colozza M, Larsimont D, Piccart MJ. Progesterone receptor testing: not the right time to be buried. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(16):3867–8. doi:10.1200/JCO.2005.05.167. author reply 9-70.
Fuqua SA, Cui Y, Lee AV, Osborne CK, Horwitz KB. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(2):931. doi:10.1200/JCO.2005.05.152. author reply 2-3.
Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res : BCR. 2013;15(4):R68. doi:10.1186/bcr3462.
Gelbfish GA, Davidson AL, Kopel S, Schreibman B, Gelbfish JS, Degenshein GA, et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg. 1988;207(1):75–9.
Horwitz KB, McGuire WL. Estrogen control of progesterone receptor induction in human breast cancer: role of nuclear estrogen receptor. Adv Exp Med Biol. 1979;117:95–110.
Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(2):203–9. doi:10.1200/JCO.2012.43.4134.
Acknowledgments
The corresponding author wishes to thank President Michael McGlothlin for his interest and support for research program at the institution.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rao, P.S., Labhart, M., Mayhew, S.L. et al. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain. Tumor Biol. 35, 7267–7273 (2014). https://doi.org/10.1007/s13277-014-1979-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-1979-9